Prenetics Global Limited (PRE)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Prenetics Global Limited (PRE) Q2 2026 Earnings Call Transcript
Prenetics Global Limited (PRE) Q2 2026 Earnings Call Transcript
TESLA AND ALPHABET SHARES SLUMP IN PRE-MARKET TRADING
Alphabet shares pare back overnight as investors scrutinise its ever-increasing capex plans. Tesla is also down after missing on earnings while free cash flow turns negative.
All You Need to Know About Prenetics Global (PRE) Rating Upgrade to Buy
Prenetics Global (PRE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
What Makes Prenetics Global Limited (PRE) a Strong Momentum Stock: Buy Now?
Does Prenetics Global Limited (PRE) have what it takes to be a top stock pick for momentum investors? Let's find out.
Prenetics Global Limited (PRE) Is Up 13.52% in One Week: What You Should Know
Does Prenetics Global Limited (PRE) have what it takes to be a top stock pick for momentum investors? Let's find out.
Prenetics: A Cautious Buy Based On Strong Sales Growth
Prenetics Global Limited is transitioning from diagnostics to a health sciences company, driven by strong IM8 supplement sales and recent asset divestitures. PRE's revenue is surging, with IM8 projected to reach $100M in annual recurring revenue and perhaps become profitable in Q1 2026. The stock is rated a cautious Buy due to growth potential, though risks include Bitcoin investments, volatile share price, and dependence on IM8's momentum.
